好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Socioeconomic Factors Associated with ≥2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States
Autoimmune Neurology
P2 - Poster Session 2 (2:45 PM-3:45 PM)
007

The objective of this study is to explore the impact of socioeconomic factors on risk of ≥2-year delayed diagnosis of NMOSD.

Consequences of delayed diagnosis in NMOSD could be as severe as complete blindness or quadriplegia.  Female sex and African ancestry are risk factors for delayed diagnosis across many disease states in the US. Patients with NMOSD are disproportionately represented by women of African descent suggesting that there may be socioeconomic barriers to timely diagnosis.

This retrospective cohort study of patients with NMOSD used a closed claims database linked with socioeconomic market research and American Community Survey data at the zip-9 level. Patients were included if they had at least 2 NMOSD claims ≥30 days apart between January 2018 and December 2021. Symptom onset was defined as the first claim of associated NMOSD symptoms up to 15 years prior to diagnosis. ≥2-year delayed diagnosis was defined as diagnosis at or after 2 years of symptom onset. The conceptual causal framework was illustrated with a directed acyclic graph. Multivariable regression models were used to estimate associations of patient characteristics and several socioeconomic variables with risk of ≥2-year delayed NMOSD diagnosis.

In multivariable regression analysis, factors associated with ≥2-year delayed diagnosis were female sex (OR 1.44; 95%CI 1.07–1.95) and Managed Medicaid coverage (OR 1.45; 95%CI 1.11–1.89). Factors associated with diagnosis in <2 years included age≤45 (OR 1.43; 95%CI 1.06–1.94), moderate and severe comorbidity [(Moderate OR 1.62, 95%CI 1.13–2.33), (Severe OR 1.56; 95%CI 1.04–2.35)], and western US regions (OR 1.56; 95%CI 1.12–2.16). There was no impact of other socioeconomic factors on ≥2-year delayed diagnosis. However, patient-level data on race/ethnicity was not available.

This study demonstrated that otherwise healthy, female, Managed Medicaid beneficiaries, age >45 years may be at highest risk for ≥2-year delayed diagnosis of NMOSD.

Authors/Disclosures
Michael Blackowicz, PhD (Alexion)
PRESENTER
Dr. Blackowicz has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Dr. Blackowicz has stock in Alexion Pharmaceuticals.
Josin James, PharmD, RPh (Alexion RDU, AstraZeneca) Dr. James has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease . Dr. James has stock in Alexion, AstraZeneca Rare Disease .
Kelly McNeil-Posey, RN (Alexion, Astra Zeneca) Mrs. McNeil-Posey has received personal compensation for serving as an employee of Alexion Pharma.
Taylor T. Schwartz, MPH Mr. Schwartz has received personal compensation for serving as an employee of Avalere. Mr. Schwartz has received personal compensation for serving as an employee of Inovalon. The institution of Mr. Schwartz has received research support from Life Sciences Organizations.
Josie Lloyd (Avalere) Josie Lloyd has received personal compensation for serving as an employee of Avalere Health. Josie Lloyd has received personal compensation for serving as an employee of Inovalon.
Nicole Betor (Avalere) Nicole Betor has received personal compensation for serving as an employee of Avalere Health.
Zhou Yang (Avalere Health) No disclosure on file